論文・技術情報追加のお知らせ

1. Comparative real-world safety profiles of selective beta1-adrenergic receptor blockers: A multi-database pharmacovigilance disproportionality study.

選択的β1遮断薬のリアルワールドにおける安全性比較評価。

対象DB：FAERS

2. Post-marketing safety of ensifentrine in COPD: A retrospective pharmacovigilance study using disproportionality analysis of FAERS/AEMS reports.

COPD治療薬エンシフェントリの市販後安全性不均衡分析。

対象DB：FAERS

3. Ephedrae Herba-Associated Adverse Events: A Disproportionality Analysis Integrated with Network Pharmacology.

麻黄関連有害事象の不均衡分析とネットワーク薬理学評価。

対象DB：FAERS,KAERS

4. Orlistat-Associated Gastrointestinal, Hepatobiliary, Pancreatic, and Anorectal Safety Signals: A FAERS Disproportionality and Regulatory Label Concordance Study.

オルリスタット関連の消化器・肝胆道有害事象シグナル解析。

対象DB：FAERS

5. Pharmacovigilance of Androgen Receptor Pathway Inhibitors in Prostate Cancer: The Impact of Docetaxel Co-Reporting.

前立腺がんにおけるアンドロゲン受容体阻害薬の安全性調査。

対象DB：FAERS

6. Agent-Specific Clinical Profiles of Antibiotic-Associated Encephalopathy: A Dual-Database Pharmacovigilance Study Using JADER and FAERS.

抗菌薬関連脳症における薬剤別臨床プロファイルの不均衡分析。

対象DB：FAERS,JADER

7. Pharmacovigilance and network toxicology analysis of risdiplam-associated adverse events in pediatric patients with spinal muscular atrophy.

リスジプラム有害事象のFAERS解析とネットワーク毒性学。

対象DB：FAERS

8. Zolbetuximab-associated adverse event reporting signals in gastric cancer: a FAERS disproportionality analysis.

ゾルベツキシマブの胃がん治療における市販後安全性シグナル。

対象DB：FAERS

9. Comparative Pharmacovigilance Analysis of Safety Signals Among Advanced Prostate Cancer Therapies Using FAERS (FDA Adverse Event Reporting System).

進行前立腺がん治療薬間における安全性シグナルの比較解析。

対象DB：FAERS

10. Drug-specific safety signal prioritization of antibody-drug conjugates in breast cancer: integrating FAERS pharmacovigilance, machine learning, and clinical contextualization.

乳がんにおける抗体薬物複合体の薬剤別安全性シグナル評価。

対象DB：FAERS

11. Characterizing bleeding adverse events associated with BCR-ABL tyrosine kinase inhibitors: insights from FAERS reports.

BCR-ABL阻害薬による出血有害事象のFAERS不均衡分析。

対象DB：FAERS

12. Post-marketing safety signal profile of mavacamten in the FDA adverse event reporting system (FAERS): a disproportionality analysis.

マバカムテンのFAERSにおける市販後安全性プロファイル。

対象DB：FAERS

13. Immune checkpoint inhibitor-related thyroid dysfunction during treatment of lung cancer: a disproportionality analysis based on the FDA adverse event reporting system.

肺がん治療におけるICI関連甲状腺機能障害の不均衡分析。

対象DB：FAERS

14. Immune checkpoint blockade reshapes drug-associated toxicity: a pharmacovigilance atlas of drug-ICI interactions.

免疫チェックポイント阻害薬併用による薬剤毒性の変化解析。

対象DB：FAERS

15. Post-marketing safety profile of Myfembree in approved gynecologic indications: a disproportionality analysis based on the FAERS database.

婦人科適応におけるミフェンブリーの市販後安全性評価。

対象DB：FAERS

16. Risk factors for drug-related cachexia: an analysis based on the FDA adverse event reporting system (FAERS) from 2004 to 2025.

薬剤関連カヘキシア（悪液質）のリスク因子とFAERS解析。

対象DB：FAERS

17. Post-marketing safety surveillance of tetanus, diphtheria, and acellular pertussis (Tdap) vaccine: a disproportionality analysis of the vaccine adverse event reporting system (2015-2025).

三種混合（Tdap）ワクチンの市販後安全性に関する調査。

対象DB：FAERS,VAERS

18. Pharmacovigilance signals and regional burden of antibiotic-associated Clostridioides difficile infection: a pharmacovigilance study and Global Burden of Disease Study 2023.

抗菌薬関連クロストリジオイデス・ディフィシル感染症解析。

対象DB：FAERS,KAERS

19. Post-Market Safety Analysis of Mirvetuximab Soravtansine: A Pharmacovigilance Analysis from a Large, Real-World Database.

ミルベツキシマブのFAERSに基づく市販後安全性評価。

対象DB：FAERS

20. Heterogeneity of thromboembolic risk across ALK inhibitors: a retrospective real-world study identifying crizotinib-specific signals and high-risk subpopulations.

ALK阻害薬間における血栓塞栓症リスクの不均衡分析調査。

対象DB：FAERS

21. A manufacturer-aware cross-system benchmark for pediatric pharmacovigilance signal concordance.

小児用医薬品の副作用検出における製造元ベンチマーク評価。

対象DB：CVAR,FAERS,JADER

22. Age-stratified adverse-event reporting signals of seven ALK/ROS1 tyrosine kinase inhibitors in FAERS: a disproportionality and time to onset study.

ALK/ROS1阻害薬7種における年齢層別副作用シグナル解析。

対象DB：FAERS

23. Comparative Risk of Nonarteritic Anterior Ischemic Optic Neuropathy Among Glucagon-Like Peptide-1 Receptor Agonists: An Integrated Safety and Mechanistic Analysis.

GLP-1受容体作動薬と非動脈性前部虚血性視神経症リスク。

対象DB：FAERS

24. Hair and Scalp Effects of GLP-1 Receptor Agonists in Practice.

実臨床におけるGLP-1受容体作動薬の毛髪・頭皮への影響。

対象DB：FAERS

25. Adverse events associated with cefuroxime ocular administration: potential demographic and dose-dependent heterogeneity assessment.

セフジニル/セフロキシム眼投与関連有害事象の人口統計解析。

対象DB：FAERS

26. Global patterns and trends in spontaneous reporting systems: VigiBase, FAERS, VAERS, and JADER.

VigiBase等世界の自発報告システムにおける傾向の比較。

対象DB：FAERS,JADER,VAERS,VigiBase

27. Drug spectrum and disproportionality signals for diabetes insipidus in FAERS: multi-method analysis, JADER cross-database assessment, and PubMed-based case-level evidence.

FAERSデータに基づく尿崩症誘発薬剤の不均衡分析調査。

対象DB：FAERS,JADER

28. Adverse event reporting signals for SGLT-2 inhibitor-metformin combination therapy: a disproportionality analysis of the FAERS database.

SGLT2阻害薬・メトホルミン併用療法の副作用シグナル評価。

対象DB：FAERS

29. Generational safety profiles of BTK inhibitors: adverse reaction signals and real-world evidence from the FAERS database.

BTK阻害薬の世代別安全性プロファイルと不均衡分析調査。

対象DB：FAERS

30. Safety profiles of calcineurin inhibitor-related infections in the pediatric population: a real-world pharmacovigilance analysis.

小児におけるカルシニューリン阻害薬関連感染症の安全性解析。

対象DB：FAERS,JADER

31. Gastrointestinal and skin safety evaluation of pirfenidone versus nintedanib: an analysis of real-world pharmacovigilance and randomized controlled trials.

ピルフェニドン対ニンテダニブの消化器・皮膚安全性比較。

対象DB：FAERS

32. Pharmacovigilance signals for congenital heart disease related to drug exposure: A disproportionality analysis based on the FAERS database.

薬剤曝露による先天性心疾患に関する自発報告不均衡分析。

対象DB：FAERS

33. Cardiovascular Safety Signals of Osteoporosis Therapies: A FAERS Pharmacovigilance Study.

骨粗鬆症治療薬の心血管安全性シグナルに関するFAERS解析。

対象DB：FAERS

34. Cross national pharmacovigilance analysis of drug-induced delirium: a comparative study using the US FAERS, Japanese JADER, and canadian CVAR datasets.

薬剤誘発性せん妄の不均衡分析に関する多国籍比較調査。

対象DB：CVAR,FAERS,JADER

35. Safety profiles of cyclosporine and tacrolimus in pregnancy: a pharmacovigilance analysis using the FDA Adverse Event Reporting System.

妊婦におけるシクロスポリンとタクロリムスの安全性比較。

対象DB：FAERS

36. Is teriparatide linked to osteosarcoma? A disproportionality analysis of the FAERS database.

テリパラチドと骨肉腫の関連性に関するFAERS不均衡分析。

対象DB：FAERS

37. Elucidating the mechanism of amikacin-induced acute kidney injury: a multilevel analysis based on the FAERS database and network toxicology.

アミカシン誘発性急性腎障害のメカニズムと不均衡分析。

対象DB：FAERS

38. Safety of eribulin: A real-world study based on a pharmacovigilance database.

エリブリンのリアルワールド安全性に関するFAERS評価。

対象DB：FAERS

39. Post-marketing safety assessment of mirvetuximab soravtansine: a disproportionality analysis based on the FDA Adverse Event Reporting System.

ミルベツキシマブの市販後安全性評価と不均衡分析調査。

対象DB：FAERS

40. Thrombotic and ischemic event reporting with anticoagulant reversal agents: a multi-agent FAERS pharmacovigilance study.

抗凝固薬中和剤投与時の血栓症・虚血イベント報告解析。

対象DB：FAERS

41. Antiemetic-Associated QT Prolongation: A Clinical Review and Risk-Stratified Prescribing Framework for Long QT Syndrome.

制吐薬に伴うQT延長リスクの臨床レビューと予防ストラテジー。

対象DB：FAERS

42. Pediatric spontaneous-reporting patterns for biologics approved or used for asthma: Analysis of the FDA adverse event reporting system.

小児喘息治療用生物学的製剤の自発報告パターン比較調査。

対象DB：FAERS

43. Ocular Surface Disease as an Immune-related Adverse Event of Immune Checkpoint Inhibitor Therapy.

免疫チェックポイント阻害薬に伴う眼表面疾患の不均衡分析。

対象DB：FAERS

44. Safety profile of entrectinib in NSCLC: Multi-source pharmacovigilance analysis using FAERS and JADER.

エヌトレクチニブのNSCLCにおけるマルチソース安全性解析。

対象DB：FAERS,JADER

45. Teclistamab-associated adverse events: a disproportionality analysis of the FDA adverse event reporting system.

テクリスタマブ関連有害事象におけるFAERS不均衡分析調査。

対象DB：FAERS

46. Real-world safety assessment of MET-targeted therapies: a pharmacovigilance analysis using the FAERS database.

MET阻害薬のリアルワールド安全性評価における不均衡分析。

対象DB：FAERS

47. Risk stratification of ibrutinib toxicity co-administered with triazole antifungals: insights from real-world pharmacovigilance and clinical evidence.

イブルチニブとトリアゾール系抗真菌薬併用時の毒性リスク。

対象DB：FAERS

48. Comparative pharmacovigilance analysis of intravenous versus oral linezolid: Insights from the FDA Adverse Event Reporting System.

静注対経口ラインゾリドの安全性プロファイルに関する比較解析。

対象DB：FAERS

49. Omadacycline-Associated Pancreatic Injury: a Spectrum from Mild Interstitial to Recrudescent Pancreatitis with Pharmacovigilance Implications.

オマダサイクリン関連膵障害のスペクトラムと不均衡分析。

対象DB：FAERS

50. Real-world pharmacovigilance signals of antibody-drug conjugates: reporting patterns by payload, linker, target, and sex in FAERS.

抗体薬物複合体（ADC）のリアルワールド安全性シグナル解析。

対象DB：FAERS

51. Increased reporting of interstitial pneumonitis with combined EGFR-TKI and PD-1/PD-L1 inhibitor therapy in NSCLC: a pharmacovigilance analysis of 67,818 reports.

EGFR-TKIと免疫チェックポイント阻害薬併用時の肺炎増加。

対象DB：FAERS

52. Retinal Detachment Reporting after Topical Pilocarpine 1.25% for Presbyopia.

局所ピロカルピン1.25%投与後の網膜剥離報告に関する調査。

対象DB：FAERS

53. Disproportionate reporting of seizures with histamine H1 receptor antagonists: The role of drug generation and brain H1 receptor occupancy assessed using the Japanese Adverse Drug Event Report database.

H1受容体拮抗薬によるけいれん報告における不均衡分析調査。

対象DB：JADER

54. Prognostic Factors Associated with Fatal Outcomes in COVID-19 Vaccine-Related Myocarditis.

COVID-19ワクチン関連心筋炎の致死性に関する予後因子。

対象DB：JADER

55. Fracture-Centred Skeletal Reporting Profiles of Glucose-Lowering Drug Classes in FAERS and JADER: Cross-Database and Regional Reporting-Context Analyses.

糖尿病治療薬9系統における骨折関連有害事象のプロファイル。

対象DB：JADER

56. Androgenetic alopecia drugs and male infertility: Evidence from pharmacovigilance and testicular transcriptomics.

男性型脱毛症治療薬と男性不妊症における不均衡分析調査。

対象DB：EudraVigilance

57. Adverse event reporting patterns of selective serotonin reuptake inhibitors (SSRIs): disproportionality analysis using the European spontaneous reporting system.

SSRI関連有害事象報告パターンの欧州データベース解析。

対象DB：EudraVigilance

58. Comparative Pharmacovigilance Analysis of Selected Cardiotoxicity Signals Associated with Doxorubicin and Epirubicin Based on EudraVigilance Data.

アンスラサイクリン系抗がん剤の心毒性シグナル比較解析。

対象DB：EudraVigilance

59. Oral antibiotics prescribing patterns and associated diarrhea risk: Public health implications.

経口抗菌薬の処方パターンと関連下痢リスクの公衆衛生解析。

対象DB：EudraVigilance

60. Haemorrhagic event reporting with concomitant gemcitabine and warfarin: a VigiBase disproportionality analysis.

ゲムシタビンとワルファリン併用における出血事象の報告解析。

対象DB：VigiBase

61. Signal Detection of Adverse Events Associated with PCSK9 Inhibitors: A Nationwide Sequence Symmetry and Combined Worldwide Disproportionality Analysis.

PCSK9阻害薬関連有害事象の全国自発報告シグナル検出。

対象DB：VigiBase

62. Distinct pattern of reported adverse event with SGLT2 inhibitors in heart failure: A pharmacovigilance study using VigiBase data.

心不全におけるSGLT2阻害薬の副作用報告パターンの解析。

対象DB：VigiBase

63. The Pitfalls of Disproportionality Analysis: Insights on Their Interwoven Complexity and a Front-End Mitigation Strategy.

不均衡分析の不確実性と限界に関する学術的考察論文。

対象DB：VigiBase

64. Turning over new stones and discovering new questions in the contributions of anaesthetic drugs to perioperative cardiac arrest.

麻酔関連心停止報告におけるVigiBaseデータシグナル解析。

対象DB：VigiBase

65. Gastrointestinal adverse events associated with axitinib: pharmacovigilance analysis of the Japanese adverse drug event report database.

アキシチニブ関連消化器系有害事象における不均衡分析調査。

対象DB：JADER

66. Perioperative outcomes of total and unicompartmental knee arthroplasty in patients with Type 2 diabetes mellitus: A propensity score-matched analysis.

2型糖尿病患者での膝関節置換術における周術期転帰の比較。

対象DB：DPC

67. Pediatric Otitis Media With Effusion Surgical Trends During COVID-19: A Time-Series Study.

COVID-19パンデミック下での小児滲出性中耳炎手術傾向解析。

対象DB：DPC

68. Short-term outcomes across sedation practice patterns in mechanically ventilated patients with bacterial pneumonia: a nationwide cohort study.

人工呼吸器装着患者における鎮静パターン別短期転帰の比較。

対象DB：DPC

69. Cost-Effectiveness of Rule-Guided Head Computed Tomography for Pediatric Head Injury: An Economic Modeling Study Using a Nationwide Claims Database.

小児頭部外傷におけるルールに基づく頭部CTの費用対効果評価。

対象DB：JMDC

70. Effects of reinfusion of ascitic fluid in malignant ascites: A nationwide claims-based cohort study.

癌性腹水患者における腹水再注入療法の効果に関する全国調査。

対象DB：NDB

71. Comparison of Nationwide Volumes for Five Major Gastrointestinal Surgical Procedures in Japan: Implications From Publicly Available NCD and NDB Open Data.

日本のNCDとNDBにおける消化器外科5手術の症例数比較。

対象DB：NDB

72. Impact of perinatal anxiety on healthcare utilisation: a matched cohort study using electronic health records in the UK.

周産期不安が医療利用パターンに与える影響の対照コホート。

対象DB：CPRD

73. Explaining variation in antibiotic prescribing for common infections: a three-way variance decomposition using UK primary care data.

英国一般診療所での普通感染症に対する抗菌薬処方変異の解析。

対象DB：CPRD

74. Temporal trends in single and multiple organ fibrosis prevalence and primary care consultations: a population-based cohort study of 5.8 million individuals in England.

単一および多臓器線維症の有病率推移に関する大規模疫学調査。

対象DB：CPRD

75. Incidence, prevalence, and life expectancy of patients with generalised pustular psoriasis in England: a population-based cohort study exploring ethnic and sex variations.

汎発性膿疱性乾癬の発症率・有病率および生命予後に関する調査。

対象DB：CPRD

76. Blood test trend versus single threshold abnormality to discriminate cancer from non-cancer in patients with unexpected weight loss: A retrospective cohort study.

不明熱・体重減少患者におけるがん鑑別のための血液検査動向。

対象DB：CPRD

77. Healthcare resource utilisation and associated costs in patients with eosinophilic granulomatosis with polyangiitis in England: A retrospective observational cohort study.

好酸球性多発血管炎性肉芽腫症患者の医療資源利用と費用負担。

対象DB：CPRD

78. Clinical Applications and Evidence Landscape of Thymosin Alpha 1 as an Immunomodulatory Adjunct in Cancer Care: A Scoping Review.

免疫調節ペプチド「サイモシンα1」の臨床応用とエビデンス。

対象DB：KAERS

79. Venous Thromboembolism in Patients Treated with Everolimus: Insights from a Case Series and the French Pharmacovigilance Database.

腎移植後のエベロリムス投与患者における静脈血栓塞栓症解析。

対象DB：FPVD

80. Association between current heated tobacco product use and incident hypertension: A nationwide real-world cohort study.

加熱式タバコ使用と高血圧発症リスクの関連性に関する調査。

対象DB：DeSC

81. Estimated Acquisition Cost Differences between Fixed and Simulated Body Weight-Based Nivolumab Dosing Using Real-World Claims Data in Japan.

ニボルマブの固定用量と体重ベース投与での薬剤コスト比較。

対象DB：DeSC